Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

about

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.

Item

http://www.wikidata.org/entity/Q40091881

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effectiveness of Ipragliflozin ...... Report of the ASSIGN-K Study.

@en

type

Item

label

Effectiveness of Ipragliflozin ...... Report of the ASSIGN-K Study.

@en

prefLabel

Effectiveness of Ipragliflozin ...... Report of the ASSIGN-K Study.

@en

P1476

Effectiveness of Ipragliflozin ...... Report of the ASSIGN-K Study.

@en

P2093

Akira Kanamori

http://www.w3.org/2001/XMLSchema#string

Akira Kubota

http://www.w3.org/2001/XMLSchema#string

Atsuko Mokubo

http://www.w3.org/2001/XMLSchema#string

Fuyuki Minagawa

http://www.w3.org/2001/XMLSchema#string

Hideaki Kaneshige

http://www.w3.org/2001/XMLSchema#string

Hideo Machimura

http://www.w3.org/2001/XMLSchema#string

Hikaru Amemiya

http://www.w3.org/2001/XMLSchema#string

Hiroshi Takeda

http://www.w3.org/2001/XMLSchema#string

Ikuro Matsuba

http://www.w3.org/2001/XMLSchema#string

Kazuaki Shinoda

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Active sugar transport in health and disease

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

P304

793-801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR3116W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28811858

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5544486

http://www.w3.org/2001/XMLSchema#string